Why Translate Bio Shares Are Trading Higher Today

Translate Bio TBIO shares are trading 9.5% higher after Roth Capital Partners raised its price target on the stock from $28 to $45.

Roth Capital Partners in a Sunday research report noted the company has one-third of its research and development funds devoted to mRNA vaccines. The firm’s $45 price target is based on the net present value of sales from a future cystic fibrosis program in the U.S., Europe and Australia as well as present royalties from the company’s mRNA-based vaccine against the flu and the COVID-19 virus. 

Translate Bio is an mRNA therapeutics company developing a new class of potentially-transformative medicines to treat pulmonary diseases caused by protein or gene dysfunction. Using its proprietary mRNA therapeutic platform, Translate creates mRNA, providing a template to replace dysfunctional proteins and encode functional proteins. The company was founded in 2011 and is headquartered in Lexington, MA. 

The stock has a 52-week low of $11.91 and a 52-week high of $33.94. 

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: MoversTrading Ideaswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!